Back to GEODE CAPITAL MANAGEMENT, LLC GEODE CAPITAL MANAGEMENT, LLC

LCTXLCTX
Showing 8 of 28 quarters

Position history for GEODE CAPITAL MANAGEMENT, LLCGEODE CAPITAL MANAGEMENT, LLC's holdings in LINEAGE CELL THERAPEUTICS IN

GEODE CAPITAL MANAGEMENT, LLC holds 5.3M shares of LCTX (LINEAGE CELL THERAPEUTICS IN), worth $6.9M as of 2026-Q2. The position was increased (+110.0% shares). LCTX represents 0.0% of GEODE CAPITAL MANAGEMENT, LLC's portfolio.

Current Value

$6.9M

Current Shares

5.3M

Total Value Change

+$3.6M

Total Shares Change

+1.6M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
5.3M
+110.0%
$6.9M0.0%$1.31
44
2026-Q1
Increased
2.5M
+2.5%
$4M0.0%$1.89
27
2025-Q4
Increased
2.5M
+1.7%
$4.1M0.0%$1.60
27
2025-Q3
Decreased
2.4M
-0.5%
$4.1M0.0%$1.79
0
2025-Q2
Decreased
2.4M
-45.8%
$2.2M0.0%$0.94
0
2025-Q1
Increased
4.5M
+21.5%
$2M0.0%$0.49
31
2024-Q4
Increased
3.7M
+0.3%
$1.9M0.0%$0.50
26
2024-Q3
Increased
3.7M
+2.3%
$3.3M0.0%$0.92
27

Other major holders of LCTX: BlackRock, Inc., VANGUARD GROUP INC, VANGUARD CAPITAL MANAGEMENT LLC, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used